Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of EMD 525797 in asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer
NL-OMON38307Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of abituzumab in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Started Jul 2011; status: active, not recruiting.
02
Drugs
abituzumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON38307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38307.